131 related articles for article (PubMed ID: 11204491)
1. Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy beagle dogs.
Sava G; Cocchietto M
In Vivo; 2000; 14(6):741-4. PubMed ID: 11204491
[TBL] [Abstract][Full Text] [Related]
2. Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.
Cocchietto M; Salerno G; Alessio E; Mestroni G; Sava G
Anticancer Res; 2000; 20(1A):197-202. PubMed ID: 10769655
[TBL] [Abstract][Full Text] [Related]
3. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
[TBL] [Abstract][Full Text] [Related]
4. Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice.
Cocchietto M; Sava G
Pharmacol Toxicol; 2000 Nov; 87(5):193-7. PubMed ID: 11129497
[TBL] [Abstract][Full Text] [Related]
5. Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
Magnarin M; Bergamo A; Carotenuto ME; Zorzet S; Sava G
Anticancer Res; 2000; 20(5A):2939-44. PubMed ID: 11062704
[TBL] [Abstract][Full Text] [Related]
6. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
7. Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.
Novohradský V; Bergamo A; Cocchietto M; Zajac J; Brabec V; Mestroni G; Sava G
Dalton Trans; 2015 Jan; 44(4):1905-13. PubMed ID: 25489765
[TBL] [Abstract][Full Text] [Related]
8. Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice.
Vadori M; Pacor S; Vita F; Zorzet S; Cocchietto M; Sava G
J Inorg Biochem; 2013 Jan; 118():21-7. PubMed ID: 23123335
[TBL] [Abstract][Full Text] [Related]
9. Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry.
Brouwers EE; Tibben MM; Rosing H; Schellens JH; Beijnen JH
Rapid Commun Mass Spectrom; 2007; 21(9):1521-30. PubMed ID: 17410551
[TBL] [Abstract][Full Text] [Related]
10. Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.
Bergamo A; Zorzet S; Cocchietto M; Carotenuto ME; Magnarin M; Sava G
Anticancer Res; 2001; 21(3B):1893-8. PubMed ID: 11497274
[TBL] [Abstract][Full Text] [Related]
11. Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine.
Sava G; Gagliardi R; Bergamo A; Alessio E; Mestroni G
Anticancer Res; 1999; 19(2A):969-72. PubMed ID: 10368640
[TBL] [Abstract][Full Text] [Related]
12. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
[TBL] [Abstract][Full Text] [Related]
13. Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration.
Cocchietto M; Zorzet S; Sorc A; Sava G
Invest New Drugs; 2003 Feb; 21(1):55-62. PubMed ID: 12795530
[TBL] [Abstract][Full Text] [Related]
14. A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Jansen MT; Sava G; Flaibani A; Bult A; Beijnen JH
Int J Pharm; 2002 Nov; 248(1-2):239-46. PubMed ID: 12429477
[TBL] [Abstract][Full Text] [Related]
15. Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.
Sava G; Frausin F; Cocchietto M; Vita F; Podda E; Spessotto P; Furlani A; Scarcia V; Zabucchi G
Eur J Cancer; 2004 Jun; 40(9):1383-96. PubMed ID: 15177498
[TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of Dimethyl Methylphosphonate (CAS No. 756-79-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1987 Nov; 323():1-172. PubMed ID: 12748730
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro.
Bicek A; Turel I; Kanduser M; Miklavcic D
Bioelectrochemistry; 2007 Nov; 71(2):113-7. PubMed ID: 17602896
[TBL] [Abstract][Full Text] [Related]
20. TGFbeta1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours.
Casarsa C; Mischis MT; Sava G
J Inorg Biochem; 2004 Oct; 98(10):1648-54. PubMed ID: 15458828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
